Centessa Pharmaceuticals PLC ADR (CNTA) is a Healthcare · Biotechnology company listed on NASDAQ. Price $40.50 (+0.80%), Market cap $6.13B, 52-week low–high $11.86 ~ $39.86.
Centessa Pharmaceuticals plc, together with its subsidiaries, discovers, develops, and delivers orexin-based neuroscience therapeutics in the United Kingdom and the United States. The company develops ORX750, an orexin receptor 2 agonist, which is in Phase IIa clinical trial for the treatment of central disorders of hypersomnolence, including narcolepsy type 1 and 2, as well as idiopathic hypersomnia. It also engages in the development of ORX142 which is in Phase I clinical trial for the treatment of neurological and neurodegenerative disorders; ORX489 which is in Phase I clinical trial for the treatment of neuropsychiatric disorders; and LockBody, an early-stage immuno-oncology program tech
Financial statements, price targets, institutional (13F) holdings and related news for Centessa Pharmaceuticals PLC ADR are updated in real time on BlackAll Trade.
Centessa Pharmaceuticals PLC ADR trades at $40.50 (+0.80%). Real-time quotes and charts are available on BlackAll Trade.
Centessa Pharmaceuticals PLC ADR has a market cap of about $6.13B.
Centessa Pharmaceuticals plc, together with its subsidiaries, discovers, develops, and delivers orexin-based neuroscience therapeutics in the United Kingdom and the United States. The company develops